Theriva Biologics, Inc.
About Theriva Biologics, Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2011
- $0
- Net income
- -$18.3M
- Total assets
- $38.2M
- Market cap
- $11.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $24.1M
- Operating income
- -$24.1M
- Net income
- -$23.7M
- EPS (basic)
- $-2.08
- EPS (diluted)
- $-2.08
Balance sheet
- Total assets
- $38.2M
- Current assets
- $17.5M
- Total liabilities
- $22.9M
- Current liabilities
- $10.0M
- Shareholders’ equity
- $15.4M
Cash flow
- Operating cash flow
- -$16.7M
- Investing cash flow
- -$35.0K
- Financing cash flow
- $18.2M
- Net cash flow
- $1.4M
Statements via Polygon.io (SEC filings)
- Market cap
- $11.7M
- EPS (diluted)
- $-2.08
- Shares outstanding
- 45.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 5, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $18.3M in FY2011.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Theriva Biologics, Inc..
Write a review
News about Theriva Biologics, Inc.
News & sentiment via Polygon.io
